Abstract
Inhaled corticosteroids (ICS) are the most common asthma controller medication. An important contribution of genetic factors in ICS response has been evidenced. Here, we aimed to identify novel genetic markers involved in ICS response in asthma. A genome-wide association study (GWAS) of the change in lung function after 6 weeks of ICS treatment was performed in 166 asthma patients from the SLOVENIA study. Patients with an improvement in lung function ≥8% were considered as ICS responders. Suggestively associated variants (p-value ≤ 5 × 10-6) were evaluated in an independent study (n = 175). Validation of the association with asthma exacerbations despite ICS use was attempted in European (n = 2681) and admixed (n = 1347) populations. Variants previously associated with ICS response were also assessed for replication. As a result, the SNP rs1166980 from the ROBO2 gene was suggestively associated with the change in lung function (OR for G allele: 7.01, 95% CI: 3.29-14.93, p = 4.61 × 10-7), although this was not validated in CAMP. ROBO2 showed gene-level evidence of replication with asthma exacerbations despite ICS use in Europeans (minimum p-value = 1.44 × 10-5), but not in admixed individuals. The association of PDE10A-T with ICS response described by a previous study was validated. This study suggests that ROBO2 could be a potential novel locus for ICS response in Europeans.
Keywords:
childhood asthma; exacerbations; forced expiratory volume in one second; genome-wide association study; inhaled corticosteroids; single nucleotide polymorphism.
Grants and funding
-
AC15/00015/Instituto de Salud Carlos III (ISCIII) through Strategic Action for Health Research (AES) and European Community (EC) within the Active and Assisted Living (AAL) Programme framework
-
SysPharmPedia/ERACoSysMed 1st Joint Transnational Call from the European Union under the Horizon 2020
-
SAF2017-83417R/Spanish Ministry of Science, Innovation, and Universities, the State Research Agency, and the European Regional Development Fund from the European Union
-
FI16/00136/ISCIII, European Regional Development Fund
-
RYC-2015-17205/Spanish Ministry of Economy, Industry and Competitiveness
-
NA/GlaxoSmithKline
-
NA/Utrecht Institute for Pharmaceutical Sciences
-
P3-0067/Slovenian Research Agency
-
C3330-16-500106/Ministry of Education, Science and Sport Slovenia
-
R01HL117004/National Heart, Lung, and Blood Institute of the National Institute of Health
-
X01HL134589/National Heart, Lung, and Blood Institute of the National Institute of Health
-
NA/Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II
-
R01ES015794/ES/NIEHS NIH HHS/United States
-
R01HL117004/National Heart, Lung, and Blood Institute of the National Institute of Health
-
X01HL134589/National Heart, Lung, and Blood Institute of the National Institute of Health
-
NA/Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II
-
099177/Z/12/Z/NHS Research Scotland and The Wellcome Trust Biomedical Resource
-
PT17/0019/ISCIII and European Regional Development Fund
-
113201006/ZONMW_/ZonMw/Netherlands
-
NA/NHS Chair of Pharmacogenetics via the UK Department of Health
-
5T32GM007546-42/National Institute of General Medical Sciences of the National Institutes of Health